Join Us:
Chief Commercial Officer FORUM
JP Morgan healthcare Conference 2023
January 10 • 4:30-6:30 PM PST
The Chief Commercial Officer (CCO) Forum is an invitation-only professional networking community intended to foster an enriching environment for biopharma commercial executives in the life sciences.
The CCO Forum is an exclusive community that brings together life sciences commercial executives to share knowledge and build relationships.
Program Fireside Chat at 5:00 pm.
Event Details:
LSC is thrilled to host Chief Commercial Officers from around the world at a networking reception during the 2023 JP Morgan Healthcare Conference in San Francisco.
Please join us to hear from BJ Jones (CCO Biohaven) and David Johnson (CCO Global Blood Therapeutics) about building organizations for successful exits.
Come enjoy an evening of hors d’oeuvres, drinks, and great connections.
Questions? Email Sheldon Ng, sng@consultingls.com
Location: Register through LinkedIn Events. You’ll receive a confirmation and the event location.
RSVP by: January 3, 2023
Patient-Centric Strategy Consulting
About LSC
LSC Lifesciences Consultants is a global management consultancy that partners with biopharma and medtech companies along their commercialization journey.
SPEAKERS
William “BJ” Jones, Jr.
Biohaven Pharmaceuticals
BJ Jones is the Chief Commercial Officer, Migraine & Common Disease of Biohaven Pharmaceuticals, a biopharmaceutical company committed to improving the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.
He has over 25 years of commercial experience in the healthcare industry and has held executive leadership roles of increasing responsibility at Takeda Pharmaceuticals, Astra Zeneca, Bristol-Myers Squibb, Boehringer-Ingelheim and NitroMed. He has significant experience in mass market product launches, including Excedrin Migraine, Abilify®, Farxiga®, Pradaxa®, BiDil® and most recently, Nurtec® ODT (rimegepant). BJ has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience (migraine, schizophrenia, bipolar, depression), cardiovascular (congestive heart failure, atrial fibrillation), diabetes (type 2 – oral and injectable), respiratory, GI, and infectious disease.
Prior to joining the pharmaceutical industry, BJ served in the U.S. Air Force and earned the rank of Major. He holds a Bachelor of Science degree in Human Factors Engineering from the U.S. Air Force Academy, a Master of Science degree in Industrial Engineering from Texas A&M University and an MBA from Stanford Graduate School of Business.
David L. Johnson
Global Blood Therapeutics, Inc.
Mr. Johnson joined GBT in March 2018 as chief commercial officer. He is responsible for creating and leading the company’s global commercial operations, including building and leading sales, marketing, business analytics and market access.
Prior to GBT, Mr. Johnson spent 15 years at Gilead Sciences, Inc., in roles of increasing responsibility. Most recently, he served as vice president, sales and marketing, Liver Disease Business Unit, where he was responsible for building and leading the company’s liver disease franchises. He was instrumental in the commercial launches of four industry leading launches in the hepatitis area.
Prior to that position, he was vice president, sales and marketing, for Gilead’s Antiviral Business Unit, where he helped launch and oversee the HIV franchise. Prior to joining Gilead, Mr. Johnson had an 11-year tenure at GlaxoSmithKline, where he held various positions in sales, product marketing, business development, global commercial strategy and portfolio development. He currently serves on the board of directors of Caribou Biosciences, a Berkeley, CA based gene therapy company. He received a B.A. in business marketing from the University of Puget Sound and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.
